Maureen Testoni News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Learn about the proposed federal bill to amend the 340B program, including changes to contract pharmacies, pharmacy benefit managers and eligibility criteria.

Judges ruled in favor of drug manufacturers' ability to limit sales and distribution of discounted drugs in the government's 340B drug pricing program.

An appeals court has upheld a lower court ruling on 340B that sided with drug manufacturers. At issue is whether pharmaceutical companies can limit distribution of discounted drugs in the 340B program. The U.S. Court of Appeals for the District of Columbia has said that they can. The May 21 ruling issued by Circuit Court Judge Gregory Katsas found for Novartis Pharmaceuticals

Federal judge rules HRSA's definition of who qualifies as a patient under the 340B drug pricing program is too narrowly defined.

CMS finalized updates to its physician fee schedule for 2024, as well as finalized the rule for next year’s Outpatient Prospective Payment System (OPPS). Provider groups are displeased with the updated rules, arguing that both physicians and provider organizations need more monetary relief than what the agency is offering.